

MADDS Expansion: I-91 Project

Massachusetts Drug Supply Data Stream (MADDS)

NEHIDTA

Traci Green Becca Olson James Downes Stephanie Thompson



+

0

Drug Supply

- Drug supply is a major determinant of drug related death
- Knowing a drug's content informs our responses
- Only known after a death, hospitalization, arrest, and often way too late to be informative, *rarely shared publicly*
- A strategy that boosts samples to toxicology and forensic labs risks overwhelming and delaying an already taxed and critical structural lab system
- Field-based tools exist and people can be trained to use them
- Protecting consumer safety is a proven prevention approach

Dissecting the Drug Supply

- Support source identification
- Signatures: Identification of new synthesis, emergence of different synthesis
 - Precursors, mediators, protective components that remain as remnants
 - Consider health effects: harmful and not harmful
- Localized alarms
- Emerging threats

Sold as: Heroin
GC/MS: 0
 Fentanyl : 80 <u>4-ANPP</u> : 20 Phenethyl <u>4-ANPP</u> : 20 <u>Cocaine</u> : 10 <u>Ethyl-4-ANPP</u> : 5 <u>Tentative Identification - See Note</u> : 5
 <u>Xylazine</u>: 5 1 <u>4F-Phenethyl-4-ANPP</u>: 2 1
 4-Fluorofentanyl : 1 0

Weak, FTIR found only Lactose; FTS+



Why do Drug Checking?

Improves safety of the drug supply (Evidence: European, darknet studies) Decreases violence in drug transactions Improves consumer knowledge and confidence Fewer unsafe adulterants/cuts Stabilizes market

Provides an opportunity for empowerment, health promotion, consumer behavior change (Evidence: FORECAST, Fentanyl Test Strip studies)

Promotes health and dignity of people who use drugs With knowledge and interaction with harm reduction staff, people change behaviors

Engagement tool for new, hard to reach populations (Evidence: RIZE MA evaluation, Peiper et al.)

Increases in program utilization, program contacts when coupling drug checking at outreach with existing medical and harm reduction services



Community drug checking focuses on supply effects for people using drugs

Community Drug Checking Program Overview

"Massachusetts style"

Samples provided from harm reduction partner site/police department and gather situational and subjective information Scan sample with FTIR (on-site), test with fentanyl/benzo/xylazine test strips (on-site), send for additional lab testing (off-site) and review by medical toxicologist Report out findings to partners, submitter, communities and the state



What is tested?

Remnant drug samples collected or donated



- How much sample? *About half of a grain of rice*
- For Police Department samples, eligible samples are *Non-criminal cases only*!
 - Controlled buy, found property, non/fatal overdose, one baggie/stamp bag = personal quantities

Real-time







Bruker Alpha FTIR

Fentanyl, Benzo, Xylazine Test Strips GCMS/LC-QToF by off-site lab

Medical Toxicology Consultation

CISIC The Center for Forensic Science Research & Education

Test with tools, interpret with care

2-3 weeks, complete testing

Talk to the donor to learn more!



What was it like? Tell us more! Information from people who use drugs can help us get better and quicker results. We ask:

- What was the sample expected to be?
- How was it used? (injected, sniffed, etc.)
- Expected OR unexpected reactions (how "normal" was it)?
- Context information
- Health problems experienced after use (abscess, seizure, overdose)
- Anything else you/they think is important



Resources

Q&A

Trends

Get App



Community Drug Checking

StreetCheck Web App www.streetcheck.org



Input data, receive results with a community designed application

Collector-Operator-Administrator Groups (community programs), Tenants (states) +Public-facing trends, limited anonymous sample data

<u>^</u>	Show 10 ¢	entries					S	Search:	
Portal 👻	Sample	ID ↑↓	Laboratory Code $\uparrow\downarrow$	Laboratory 1	Status 1	Collected By $\uparrow\downarrow$	Collected On $\uparrow\downarrow$	Modified On $\uparrow \downarrow$	Action
Roles		HST_678			Untested		02/22/2023	02/22/2023	20
ontent Modules ctionary	101.40 101.40	HST_683			Untested		02/22/2023	02/22/2023	0
abels amples -		MA589			Untested		02/22/2023	02/22/2023	20
les		NHT_0639			Untested		02/22/2023	02/22/2023	20
mples		HST_0709	1238	DrugsData	Initial		02/22/2023	02/22/2023	20
•	AM	NHT_0638	1209	CFSRE	Initial		02/22/2023	02/22/2023	20

 \checkmark

 $\pmb{\Phi}_{o}^{o}$

€

<u>.ud</u>

Current Community drug checking program sites*

PURPLE=**MADDS**, Massachusetts Public Health Dept

GREY=Sites in progress

YELLOW = NIH- and FORE-funded research projects

RED=I-91 project (Overdose Response Strategy, ONDCP/CDC Foundation)

*Data from all sites pooled on StreetCheck for transparency and sharing



I-91 Project

Community Programs, Locations	ORS Team
VT: AIDS Project of Southern VT (Brattleboro, Bennington)	James Downes (DIO) Stephanie Thompson (PHA)
CT: Connecticut Harm Reduction Alliance (Hartford), Yale Syringe Service Program (New Haven), Liberation Programs (Bridgeport)	Bobby Lawlor (DIO) Anna Gasinksi (PHA)
Western MA: Tapestry Health (Holyoke, Greenfield)	Mike Sampson (DIO) Amanda Consigli (PHA)



I-91 Project Site Partners

Harm reduction organizations

- Bridgeport, New Haven, Hartford
- Holyoke, Greenfield
- Brattleboro, Bennington

Willing to work in collaboration with ORS partners to implement project



Orientation, **Training**

- Site visits to share, meet staff, prepare space
- Online and in-person trainings, refresher
- Ongoing supports, consultations
- Learning collaborative, drop-ins



What did and didn't happen with public safety partners?

- No police departments in any of the sites provided samples for testing or participated as an active site
 - State-specific challenges: staffing/personnel, permissions, uncertainty in direction from courts
- <u>All</u> police departments engaged in multiple meetings with the team and provided active or tacit (written) support of the project
- Reconnected with community harm reduction partners
- "New page" in post-COVID-19 era efforts

Getting to 'Yes': Innovations in Permissions

Memorandum of Understanding-style

MEMORANDUM OF UNDERSTANDING

BETWEEN

BRANDEIS UNIVERSITY

AND

BERKSHIRE DISTRICT ATTORNEY'S OFFICE

The Berkshire District Attorney's Office and Brandeis University, a Massachusetts not for profit corporation with an address of 415 South Street, Waltham, MA enter into this Agreement as of August 5, 2020 (the "Effective Date").

WHEREAS, fatal opioid overdoses have risen 450% in Massachusetts since 2000, and understanding the rapidly changing epidemic from the viewpoint of active drug users would add greatly to the understanding of the fentanyl crisis and opportunities for prevention and response;

WHEREAS, the Centers for Disease Control and Prevention ("CDC") is funding and supporting the continuation of the "Rapid Assessment of Consumer Knowledge Project" (the "RACK" Study);

WHEREAS, Brandeis is participating in a component of the RACK Study by conducting surveillance of packaging detritus (trash) and other donated and discarded materials used by people who use drugs to determine the presence and composition of any remnant substance;

WHEREAS, this approach conducts public health surveillance of the discarded detritus of the opioid epidemic relying upon materials found in public places, abandoned spaces, and otherwise donated or intended for public disposal (i.e, to a transfer station or other disposal facility);

WHEREAS, Brandeis University, led by Traci C. Green, PhD, MSc, is cataloging this detritus as part of the RACK Study;

WHEREAS, Dr. Green and her team (the "Brandeis Research Team") will obtain, catalogue the detritus, test it, and dispose of it as originally intended;

WHEREAS, Berkshire county police departments, as designated and agreed upon, and other community partners in Berkshire obtain detritus that may be useful to the RACK Study and wishes to provide the detritus to Dr. Green and her team of researchers for use in the RACK Study; and

WHEREAS, Brandeis University and the Berkshire District Attorney's Office (the "Parties") wish to memorialize their understanding of how they will work together to support the RACK Study.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter expressed, the sufficiency and receipt of which is hereby acknowledged, the Parties hereto, intending to be legally bound, agree as follows:

1. The Berkshire District Attorney's Office (BDAO) will support the RACK Study by:

Memo-style



Holyoke Police Department 138 Appleton Street Holyoke, Massachusetts 01040-5706



August 1, 2022

Cheryl Zoll Tapestry Health Systems, Inc. 1985 Main St. 2nd Floor, Ste. 202 Springfield, MA 01103

CF 0149-22

Dear Ms. Zoll,

We at the Holyoke Police Department recognize that fatal opioid overdoses have risen 450% in Massachusetts since 2000, and we understand the rapidly changing epidemic from the viewpoint of active drug users would add greatly to the understanding of the fentanyl crisis and opportunities for prevention and response. We also understand that the New England High Intensity Drug Trafficking Area ("NEHIDTA") is funding and supporting the "I-91 Drug Checking Project (I91DC)", which is an expansion of the Massachusetts Drug Supply Datastream and related efforts referred to more broadly as the Streetcheck Drug Supply Datastream.

We understand and support that Brandeis University Research Staff, Tapestry Health program staff and/or other program staff will be collecting, cataloging, scanning, and sending for confirmatory testing via authorized routes and disposing of remnant drug and packaging detritus at the Tapestry Health site in the City of Holyoke pursuant to appropriate Brandeis University and Drug Enforcement Agency protocols, policies and procedures. We also understand that this project will involve the collection of remnant drug trash (e.g. once used cottons and cookers, residue in wax bags) and that clients will go to Tapestry for the purpose of donating remnant drug trash to participate in the program.

Good luck with the project and we support these efforts for the safety and wellbeing of all in our community.

Please let me know if you have any questions.

	Presence of Xylazine in Samples - Over Time	Presence of Fentanyl in Samples - Over Time	Combinations of Active Cuts Detected in Samples - Over Time	Active Cuts Detected by Primary Chemical	
	Inactive Cuts Detected by Primary Chemical	Expected vs Detected Primary Chemical	Most Common Active Substances Detected by Sample Origin	Breakdown of Fentanyl Analogues Detected	
	Results	All community partner sites fully operational Over 500 samples collected and tested across the project sites in one year			
All data and quick reports publicly acces Streetcheck.org by state, or together				accessible on ther	



Xylazine • Positive • Negative

Xylazine Prevalence in Opioids

- Across CT, MA, VT samples
- Opioid samples only, over time
- Detected as pills (M30, Percocet) and powders (heroin/dope/fentanyl)
- Some local trends: brown or color used to differentiate from white powders



So, it's present, but how much Xylazine is in a given drug?

Quantification (% weight)

CFSRE weighs samples of 10mg+

Derives % inactive drug, % fentanyl/analogs (purity ratio), % heroin, % xylazine

High variability

In contrast, Philadelphia xylazine ranges 25%-40% weight

Lessons learned: Can community drug checking be adapted to other states, rural areas?

- Interfaces with mobile outreach work well
- Can fit into clinical space, phlebotomy space, office space, big or small
- Harm reduction staff can be trained to conduct all aspects of program
- Mailing samples is less preferable to real-time testing and should be available to all, especially rural partners



Lessons Learned

Community harm reduction organizations are true experts and do amazing things with this tool in their toolbox

 "We've learned it's important to offer drug trash checking services before someone consumes a substance, as well as after there is an adverse health event. Testing before use helps people to make informed decisions about what they are putting in their bodies and we can use this information to reduce risk of overdose. Testing after use is beneficial for information purposes and for research purposes related to the drug supply. Both are important and have value!"

Lessons Learned

- Collaboration with ORS partners was critical for talking with local leadership and law enforcement
- StreetCheck is a versatile platform and can be adapted and used in other states
- Diversify labs
- Legislative action may be needed
- Whenever possible, avoid starting a multi-state community project during a pandemic ⁽³⁾

Addressing Barriers and Challenges

"The biggest barriers or challenges we face with this are probably **stigma** and **fear of perceived consequence by the person getting their drug trash tested**."

- Provided small incentives (\$5 giftcards) to support outreach team's initial discussions
- Business cards, incorporate into outreach messaging
- Secure highest level legal and other permissions as possible to protect staff, participants
- Invest in collaborations, communications with public health and public safety

Permissions and MOUs

- Memo (CT, MA)
- State's Attorneys meetings
- Tenacity and persistence

Supply chain delays in instruments, supplies

Mail-based initial sample collection

Staffing constraints (public safety)

• Focus on community program scale-up





This project was supported by Grant No. 621990/NDCP03A awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy of the United States Government. Research current as of September 2022.

https://legislativeanalysis.org/model-fentanyl-teststrip-and-other-drug-checking-equipment-act/

How people use the data

"We are using our drug trash checking results to create different forms of communication to people who are at risk of overdose to inform them about what is in their substances. In addition to testing samples for people who use drugs, there is also value to testing samples and sharing results with people who sell drugs. For example, during a nationwide Adderall shortage, one person who took part in the drug checking initiative learned that what they were selling were pressed meth pills. Since learning this, the person informed the people purchasing the Adderall pills what is actually in them. In turn, the people purchasing them are now better equipped with understanding what they are putting in their body and how it will affect their body differently."

How people use the data

"We use our results to inform participants of trends, monitor above average fentanyl surges, and tailor or pivot our outreach (ex. adding more wound care or focusing on an area with high overdose rates)."

Supply caretaking: To explore local drug market trends (dilution, adulterating), reflect back anomalies, and also share helpful actions that suppliers are taking or could take.

How people use the data

Developing new partnerships, reaching new demographics of PWUD to share information, drug checking services, and connecting to other harm reduction services and materials

- More racially and geographically diverse groups of PWUD
- PWUD by different routes of administration (oral, insufflation) who may not otherwise attend SSPs

Typical sample



	Toran and Wellington and and
	and the second s
	and the second
ŏ	
8	
	14X
	2.2
	1.1.2

Initial Analysis

FTIR Results	
Substance	Component
Lactose	Major
Mannitol	Minor
Fentanyl / Analogue	Trace
Xylazine	Minor

(Initial) Location Massachusetts Massachusetts Awaiting Laboratory Analysis

This sample probably contains mostly 'Lactose' with 'Mannitol, Xylazine' and trace levels of 'Fentanyl / Analogue'

- Injected: normal, nothing out of the ordinary
- Weaker than old dealer but consistent with new dealer
- Normal experience, all from same dealer, same day use

Drug checking: more than just alerts

What is "normal", what can be expected

Promotes dignity, awareness, selfcare

Learning opportunity

Atypical samples

March 2023





Used, stronger than

Result

Component

Major

Major

Minor

5

2

_ocation

Initial

1 Massac

usual, developed

abscesses

Component

Wk 1: Not yet used

Active Component	Ratio	Active Compon
Xylazine	200	Xylazine
Fentanyl	100	Fentanyl
4-ANPP	50	4-ANPP
Heroin	1	
FTIR Results		FTIR Results
		Substance

Substance	Component	Substance
Xylazine	Major	Xylazine
Fentanyl	Major	Fentanyl
Mannitol	Minor	Mannitol

April 2023

Wk 5: Multiple overdoses (nonfatal, fatal)

FTIR Results	
Substance	Component
Xylazine	Major
Fentanyl	Major
Mannitol	Unknown



Injected: stronger than usual, tasted
and smelled like CHEMICALS.

No "dope rush", just went out. Only used 3 bags vs. usual 5-10. On second use, felt foggy, hard time walking.

		Onknown	
ocation assachuse	etts	Suspected a Heroi	s n
Awaiting L	Laboratory Analysis		
Initial Ana	lysis	This sample probably contains mostly 'Xylazine, Fentanyl' and unknown levels of 'Mannitol'	
Ke ‼ No Xyla:	ey Findings te that this stamp is associate zine is a strong sedative and	ed with several severe overdoses in the local area. Please take care and keep plenty of naloxone with you!! high amounts of a strong sedative can be harmful. Learn more here.	

2023 ORS Conference MADDS Drug Checking Program in Vermont



James G. Downes, III, MS, Drug Intelligence Officer, ORS

Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Drug Intelligence Officers (DIO)

- Partner with public health agencies and public health analysts to bridge communication gap with public safety
- DIOs fill a critical gap in intelligence sharing by:
 - reporting cross-jurisdictional links
 - communicating interstate intelligence
 - relaying case referrals between agencies
 - developing timely intelligence reports for law enforcement audiences

Introduction

Relationship Building Leverage existing Relationships Identifying Champions Sharing the Vision and Mission Setting the Table Partner Needs Information Gaps Establishing and Maintaining program Credibility and Accountability



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Relationship Building

Relationship Building is Continuous and Evolving



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Setting the Stage

DIO and PHA Positioned Well Know the Environment Know the Stakeholders Existing Environment both Socially, Politically and Economically What are the Local Issues Who are the Champions



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Leveraging Existing Relationships

DIO and PHA Leverage Relationships in both Public Safety and Public Health



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Partner Needs

Identify Partner Needs and Local issues



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Information Gaps

Gaps in Drug Supply Harm Reduction Gaps Outreach Gaps in Information Lack of Data Analysis



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

VISION and Mission

Clearly articulate the vision Share Mission Statement Align with partners mission and values



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Maintaining Program Integrity and Accountability



Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Current Status

VT Legislation Opioid Settlement Funding to support state-wide program investment VT DOH leadership





Funded by the Office of National Drug Control Policy and the Centers for Disease Control and Prevention

Thank you! Questions? Contact tracigreen@brandeis.edu Beccaolson@brandeis.edu jdownes@nehidta.org sthompson@nehidta.org

Thanks to our MADDS team Cole Jarczyk, Staci Sullivan, Sharon Lincoln, Rachel Wightman, Alex Krotulski, Brandon del Pozo, Gail Hall, Dave Vaccaro, Adina Badea, and to our funders CDC, SAMHSA, HIDTA directors SDC

OPEN

Implementation and Uptake of the Massachusetts Drug Supply Data Stream: A Statewide Public Health-Public Safety Partnership Drug Checking Program

Traci C. Green, PhD, MSc; Rebecca Olson, MPH; Cole Jarczyk, BA; Earth Erowid, BA; Fire Erowid, BA; Sylvia Thyssen, BA; Rachel Wightman, MD; Brandon del Pozo, PhD, MPA, MA; Laura Michelson, MSW; Amanda Consigli, MPH; Brittni Reilly, MSW; Sarah Ruiz, MSW, MPH

ABSTRACT

Context: The illicit drug supply is rapidly evolving. Equally important to gathering drug supply data for monitoring is timely sharing of information with people who use drugs, the providers who care for them, law enforcement partners, and public health stakeholders so that efforts to avoid harmful substances, take preventive actions, and better target interventions can occur.

Program: The Massachusetts Drug Supply Data Stream (MADDS) is the country's first statewide community drug checking program. Founded on public health-public safety partnerships, MADDS collects remnant drug packaging and paraphernalia with residue from people who use drugs and noncriminal samples from partnering police departments. MADDS tests samples using simultaneous immunoassay fentanyl test strips, Fourier-transform infrared spectrometry (FTIR), and off-site laboratory testing by gas chromatography-mass spectrometry (GC/MS). Results are accessible to community programs and municipalities, while trend analyses inform public health for cross-site alerts and informational bulletins.

Implementation: MADDS was launched statewide in 2020 and rapidly expanded to a multisite program. Program staff approached communities and met with municipal police and community partners to secure written agreements to host drug checking. Community partners designed sample collection consistent with their pandemic era workflows. Consultations with stakeholders gathered feedback on design and deliverables.

Evaluation: The program tests sample donations on-site from community agencies and police departments, incorporates review by a medical toxicologist for health and safety concerns, crafts stakeholder-specific communications, and disseminates English, Spanish, and Portuguese language materials. For 2020, a total of 427 samples were tested, of which 47.1% were positive for fentanyl. By early 2021, MADDS detected shifts in cocaine purity, alerted communities of a new toxic fentanyl analogue and a synthetic cannabinoid contaminant, and confirmed the increase of xylazine (a veterinary sedative) in Massachusetts.

Discussion: Community drug checking programs can be collaboratively designed with public health and public safety to generate critical health and safety information for people who use drugs and the communities where they live.

KEY WORDS: consumer safety, drug checking, fentanyl, harm reduction, overdose